[Skip to Content]
[Skip to Content Landing]
Views 359
Citations 0
Comment & Response
May 16, 2019

Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer

Author Affiliations
  • 1Section of Hematology, Department of Internal Medicine, Yale University, New Haven, Connecticut
  • 2Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, Connecticut
JAMA Oncol. 2019;5(7):1066. doi:10.1001/jamaoncol.2019.1088

To the Editor Criss et al1 report the results of a cost-effectiveness analysis comparing durvalumab consolidation therapy with no consolidation therapy for stage III non–small cell lung cancer (NSCLC). Although the analysis offers unique strengths, several model assumptions create doubt about the conclusion that durvalumab consolidation therapy is cost-effective at a willingness-to-pay threshold of $100 000 per quality-adjusted life year.

×